Concepedia

Publication | Closed Access

INTRAVITREAL INJECTION OF 2.5 mg VERSUS 1.25 mg BEVACIZUMAB (AVASTIN) FOR TREATMENT OF CNV ASSOCIATED WITH AMD

DOI

54

Citations

25

References

2009

Year

Mehdi Modarres, Masood Naseripour, Khalil Ghasemi Falavarjani, Aminollah Nikeghbali, Masih Hashemi, Mohammad Mehdi Parvaresh
Retina

Abstract

Intravitreal injection of 2.5 mg bevacizumab has the same efficacy as 1.25 mg, but may be associated with a higher rate of adverse events.

References

YearCitations

Page 1